Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Lawitz

Showing results (91-100 of 157) with videos related to

Pageof 16
Sort By:
Medicine|July 3, 2019
Real-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillanceNicole Loo, Bryan Hanysak, Jena Mann, et al.
Hepatology (Baltimore, Md.)|October 23, 2016
Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trialEric Lawitz, Fred Poordad, Julio A Gutierrez, et al.
Antiviral Therapy|August 9, 2014
Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis CEric Lawitz, Daniel Gruener, Thomas Marbury, et al.
Kidney International Reports|February 19, 2019
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney DiseaseEric Lawitz, Edward Gane, Eric Cohen, et al.
The New England Journal of Medicine|October 12, 2017
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal ImpairmentEdward Gane, Eric Lawitz, David Pugatch, et al.
Hepatology (Baltimore, Md.)|October 24, 2009
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonrespondersVinod K Rustgi, William M Lee, Eric Lawitz, et al.
Hepatology (Baltimore, Md.)|October 12, 2007
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virusJohn G McHutchison, Bruce R Bacon, Stuart C Gordon, et al.
Gastroenterology|March 8, 2014
Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trialXavier Forns, Eric Lawitz, Stefan Zeuzem, et al.
The New England Journal of Medicine|June 7, 2024
A Phase 2 Randomized Trial of Survodutide in MASH and FibrosisArun J Sanyal, Pierre Bedossa, Mandy Fraessdorf, et al.
Antiviral Research|June 11, 2013
Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokineticsEric Lawitz, Mark Sulkowski, Ira Jacobson, et al.
Pageof 16

Showing results (91-100 of 157) with videos related to

Sort By:
Pageof 16
Medicine|July 3, 2019
Real-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillanceNicole Loo, Bryan Hanysak, Jena Mann, et al.
Hepatology (Baltimore, Md.)|October 23, 2016
Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trialEric Lawitz, Fred Poordad, Julio A Gutierrez, et al.
Antiviral Therapy|August 9, 2014
Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis CEric Lawitz, Daniel Gruener, Thomas Marbury, et al.
Kidney International Reports|February 19, 2019
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney DiseaseEric Lawitz, Edward Gane, Eric Cohen, et al.
The New England Journal of Medicine|October 12, 2017
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal ImpairmentEdward Gane, Eric Lawitz, David Pugatch, et al.
Hepatology (Baltimore, Md.)|October 24, 2009
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonrespondersVinod K Rustgi, William M Lee, Eric Lawitz, et al.
Hepatology (Baltimore, Md.)|October 12, 2007
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virusJohn G McHutchison, Bruce R Bacon, Stuart C Gordon, et al.
Gastroenterology|March 8, 2014
Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trialXavier Forns, Eric Lawitz, Stefan Zeuzem, et al.
The New England Journal of Medicine|June 7, 2024
A Phase 2 Randomized Trial of Survodutide in MASH and FibrosisArun J Sanyal, Pierre Bedossa, Mandy Fraessdorf, et al.
Antiviral Research|June 11, 2013
Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokineticsEric Lawitz, Mark Sulkowski, Ira Jacobson, et al.
Pageof 16